Baricitinib (Olumiant), a small molecule JAK1/JAK2 inhibitor, is approved for the treatment of rheumatoid arthritis (RA) and has been proven to reduce lung fibrosis and inflammation in patients with RA-associated ILD (RA-ILD) [110]. This evidence concerns the gene JAK2 and rheumatoid arthritis.